After quietly plowing the arid cancer vaccine field for a decade, a low profile Swiss biotech is throwing itself in the ring as a player to watch in the frenetic race to extend the benefits of immunotherapies to solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,